Servier Announces FDA Approval of Voranigo (Vorasidenib) for Post-Surgical Treatment of IDH1/2-Mutant Grade 2 Glioma in Patients Aged 12 and Older

August 6, 2024 (Boston)

Servier announces U.S. approval of Voranigo (vorasidenib) for the treatment of patients with susceptible mutations after surgery.IDH1OrIDH2Adult and pediatric patients aged 12 years and older with mutant grade 2 astrocytoma or oligodendroglioma.

Voranigo is the first systemic therapy approved by the FDA for the treatment of the aforementioned patients.

Voranigo（vorasidenib）

Vorasidenib is an orally available, brain-penetrant, and selective dual inhibitor that targets mutant IDH1/2 proteins. IDH1 and IDH2 are crucial targets in cancer treatment through the modulation of tumor metabolic pathways. Patients with glioma can effectively manage their condition by taking a single pill once daily.

Glioblastoma (GB)Tumors originating from glial cells or precursor cells within the central nervous system (CNS). Gliomas are a form of brain cancer that impede normal brain function and cause various symptoms. Diffuse gliomas with IDH mutations are the most common malignant primary brain tumors in adults under the age of 50.

Rare Neurological Disorders Communication Group

↓Click " belowRead the original text", DownloadMedSci Medical APP!